Acipimox

DB09055ApprovedInvestigationalSmall molecule

Acipimox is a niacin derivative used in Fredrickson type IIb and type IV hyperlipoproteinemia. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid.

Chemical structure of Acipimox
Mechanism
Curator reviewed
Primary indication
Used in the treatment of hyperlipidemias (abnormally elevated levels of any or all lipids and/or lipoproteins in the blood).Curator reviewed · 2 structured indications
Formula / weight
C6H6N2O3 · 154.125 g/mol (avg)

Resolves to

Compound
UNIIK9AY9IR2SDCAS51037-30-0ChEMBLCHEMBL345714ChEBI94688PubChem5310993KEGGD07190
Clinical / RWD
RxNorm16817ATCC10AD06
Structure
InChIKeyDJQOOSBJCLSSEY-UHFFFAOYSA-NSMILESCC1=[N+]([O-])C=C(N=C1)C(O)=O
Targets
Q8TDS4HCAR2O60678PRMT3Q05469LIPE

What you can answer from here — as of July 03, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
97Drug interactionsStructured to mechanism, not free text
Sign in
20Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
5Marketed productsAcross 4 countries and 2 labellers
Sign in
1ATC codeIncluding every combination product, plus 6 drug categories
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Acipimox, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In